Contents
As the heart of Illinois, Chicago is a leader in medical research and innovation. The city sets a high standard for healthcare.
Clinical Research in Chicago
Board-certified physicians and licensed clinicians in Chicago are constantly looking for new ways and therapies to treat different diseases. They do this mostly through clinical trials. Your support keeps them going.
Participating in a clinical trial helps experts collect key insights and data on your personal experience. This can help future patients acquire safer treatments.
If you are interested in signing up for a trial in Chicago, then you are in the right place. We are here to streamline the whole process and connect you with reputable facilities in your local area.
Clinical Trials For Disease Areas in Chicago
Research studies in Chicago, IL cover a broad spectrum of transitional science. They range from pediatric care, neurological conditions, and respiratory health to a collection of genetic and other biomarkers in medicine.
A major focus in clinical trials is finding new treatments and diagnostic tools that provide meaningful clinical advantages.
Some studies assess diseases like sickle cell disease and diabetic foot infections. Whereas others evaluate clinical conditions that could be relevant to patients across various diagnoses, such as cardiopulmonary resuscitation (CPR) quality and pain control.
For example, the University of Chicago Medical Center has enrolled more than 100,000 patients in clinical trials since 1997. They’ve enrolled an extra 20,000 patients at other healthcare facilities across the nation for multicenter studies.
In fact, UChicago Medicine has the biggest number of clinical trials in the region. In the past year, they’ve recruited over 1,000 patients for cancer medical research.
Because of the wide range of clinical trials in Chicago, there is always a need for more volunteers. Our platform connects you with leading researchers and facilities near you. Join us as we make a lasting impact on healthcare. Sign up now!
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
Recruiting
RATIONALE: Congenital toxoplasmosis is an infection caused by the parasitic organism Toxoplasma gondii, and it may be passed from an infected mother to her unborn child. The mother may have mild symptoms or no symptoms; the fetus, however, may experience damage to the eyes, nervous system, skin, and ears. The newborn may have a low birth weight, enlarged liver and spleen, jaundice, anemia, petechiae, and eye damage. Giving the antiparasitic drugs pyrimethamine and sulfadiazine is standard treatm... Read More
RATIONALE: Congenital toxoplasmosis is an infection caused by the parasitic organism Toxoplasma gondii, and it may be passed from an infected mother to her unborn child. The mother may have mild symptoms or no symptoms; the fetus, however, may experience damage to the eyes, nervous system, skin, and ears. The newborn may have a low birth weight, enlarged liver and spleen, jaundice, anemia, petechiae, and eye damage. Giving the antiparasitic drugs pyrimethamine and sulfadiazine is standard treatment for congenital toxoplasmosis, but it is not yet known which regimen of pyrimethamine is most effective for the disease.
PURPOSE: Randomized phase IV trial to determine which regimen of pyrimethamine is most effective when combined with sulfadiazine and leucovorin in treating patients who have congenital toxoplasmosis. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
05/13/2009
Locations: University of Chicago, Chicago, Illinois
University of Chicago, Chicago, Illinois
Conditions: Toxoplasmosis
Delirium Prevention Protocol in Elderly Patients
Recruiting
The current study aims to elucidate the effectiveness of a preventative delirium protocol in patients older than 65 years of age undergoing elective surgery.
The current study aims to elucidate the effectiveness of a preventative delirium protocol in patients older than 65 years of age undergoing elective surgery. Read Less
Gender:
All
Ages:
Between 65 years and 89 years
Trial Updated:
07/07/2020
Locations: Rush University Medical Center, Chicago, Illinois
Rush University Medical Center, Chicago, Illinois
Conditions: Delirium
SIESTA for Acute Stroke Rehabilitation
Recruiting
The SIESTA-Rehabilitation protocol combines two sleep-promoting interventions, (1) empowering nurses to reduce unnecessary disruptions and (2) a systematic protocol to screen, diagnose, and treat sleep-disordered breathing, to determine its impact on relevant sleep and rehabilitation outcomes in the acute inpatient stroke rehabilitation setting compared to the standard of care. Our primary outcome is change in Quality Indicator (QI) score, a measure that has replaced the Functional Independence... Read More
The SIESTA-Rehabilitation protocol combines two sleep-promoting interventions, (1) empowering nurses to reduce unnecessary disruptions and (2) a systematic protocol to screen, diagnose, and treat sleep-disordered breathing, to determine its impact on relevant sleep and rehabilitation outcomes in the acute inpatient stroke rehabilitation setting compared to the standard of care. Our primary outcome is change in Quality Indicator (QI) score, a measure that has replaced the Functional Independence Measure (FIM) in the inpatient setting at the Shirley Ryan AbilityLab, between admission and discharge. Read Less
Gender:
All
Ages:
18 years and above
Trial Updated:
02/03/2022
Locations: Shirley Ryan AbilityLab, Chicago, Illinois
Shirley Ryan AbilityLab, Chicago, Illinois
Conditions: Stroke, Sleep-Disordered Breathing
TXA in Spine Surgery
Recruiting
As tranexamic acid (TXA) becomes more prevalent, all patients are receiving the same dose and method of delivery regardless of their pre-operative risk of transfusion. Therefore, the aim of the study is to determine whether or not repeated dosing of oral or a different method of delivery like intravenous (IV) TXA reduces the post-operative reduction in hemoglobin, hematocrit, number of transfusions, and postoperative blood loss following open spine surgery.
As tranexamic acid (TXA) becomes more prevalent, all patients are receiving the same dose and method of delivery regardless of their pre-operative risk of transfusion. Therefore, the aim of the study is to determine whether or not repeated dosing of oral or a different method of delivery like intravenous (IV) TXA reduces the post-operative reduction in hemoglobin, hematocrit, number of transfusions, and postoperative blood loss following open spine surgery. Read Less
Gender:
All
Ages:
18 years and above
Trial Updated:
12/11/2020
Locations: Rush University Medical Center, Chicago, Illinois
Rush University Medical Center, Chicago, Illinois
Conditions: Postoperative Blood Loss Following Spine Surgery
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
Recruiting
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL.
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL. Read Less
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
01/14/2022
Locations: Research Site, Fountain Valley, California +1 locations
Research Site, Chicago, Illinois
Research Site, Chicago, Illinois
Conditions: Chronic Lymphocytic Leukemia
Study to Evaluate The Safety and Efficacy of Balovaptan in Patients With Acute Ischemic Stroke at High Risk of Developing Malignant Brain Edema
Recruiting
This study is designed to evaluate the safety, efficacy, and pharmacokinetics of balovaptan compared with placebo in participants with acute ischemic stroke (AIS) at risk of developing malignant cerebral edema (MCE)
This study is designed to evaluate the safety, efficacy, and pharmacokinetics of balovaptan compared with placebo in participants with acute ischemic stroke (AIS) at risk of developing malignant cerebral edema (MCE) Read Less
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/04/2022
Locations: University of Alabama At Birmingham, Birmingham, Alabama
Northwestern Memorial Hospital, Chicago, Illinois
Conditions: Acute Ischemic Stroke
Enhanced Medical Rehabilitation for Spinal Cord Injury
Recruiting
To achieve higher levels of patient engagement, it is important to improve therapists' techniques for goal setting and clinician-therapist communication. Thus, the investigators have developed a manualized intervention for post-acute rehabilitation, Enhanced Medical Rehabilitation (EMR), which is an evidence-based program to increase patient engagement and achieve a greater intensity of therapy, thereby optimizing the patient's functional and psychosocial recovery. EMR is an integrated set of sk... Read More
To achieve higher levels of patient engagement, it is important to improve therapists' techniques for goal setting and clinician-therapist communication. Thus, the investigators have developed a manualized intervention for post-acute rehabilitation, Enhanced Medical Rehabilitation (EMR), which is an evidence-based program to increase patient engagement and achieve a greater intensity of therapy, thereby optimizing the patient's functional and psychosocial recovery. EMR is an integrated set of skills for occupational and physical therapists that transform rehabilitation through (1) a patient-directed, interactive approach; (2) increased treatment intensity; and (3) frequent feedback to patients on effort and progress.
The investigators have developed training and supervision methods to enable therapists to carry out these skills with high fidelity. Due to the complexity of the inpatient spinal cord injury (SCI) rehabilitation environment, it is unknown whether the EMR program will be clinically relevant to inpatient rehabilitation settings and acceptable to SCI populations. Therefore, it is necessary to conduct a systematic adaptation approach to address all barriers, and test this adapted program to a new setting (inpatient rehabilitation) and a new population (patients with SCI), without compromising the core elements of the original EMR.
Objective: The investigators propose to adopt the EMR program for use in inpatient SCI rehabilitation settings using an implementation science. The investigators propose a randomized trial of 80 patients with SCI to test the effects of EMR on improving engagement and treatment intensity, as well as functional and psychosocial outcomes over standard of care (SOC) rehabilitation.
Methods: The investigators will randomize patients into EMR or SOC groups. For the EMR group, four therapists will be trained and supervised in EMR and will incorporate EMR techniques into therapy sessions. In the SOC group, four therapists will carry out therapy sessions as usual.
Outcomes: With respect to EMR intervention adaptions, the investigators hypothesize that the EMR program, including a treatment manual and other materials, will be customized with input from our Spinal Cord Injury-Community Advisory Board (SCI-CAB). Patients randomized to EMR will have greater engagement and intensity and greater functional and psychosocial recovery compared to those randomized to SOC rehabilitation.
Significance: Success in this research will improve therapists' skills working with patients and optimizing patient outcomes Read Less
Gender:
All
Ages:
18 years and above
Trial Updated:
05/03/2022
Locations: Shirley Ryan Ability Lab, Chicago, Illinois
Shirley Ryan Ability Lab, Chicago, Illinois
Conditions: Spinal Cord Injuries
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
Condition or disease:
Breast Cancer
Intervention/treatment:
Drug: Gedatolisib
Drug: Palbociclib
Drug: Fulvestrant
Drug: Alpelisib
Phase 3
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
Condition or disease:
Breast Cancer
Intervention/treatment:
Drug: Gedatolisib
Drug: Palbociclib
Drug: Fulvestrant
Drug: Alpelisib
Phase 3 Read Less
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Rush University Medical Center, Chicago, Illinois
Conditions: Breast Cancer
Ablation-Index Guided Ventricular Tachycardia Ablations
Recruiting
Over the last decade, radiofrequency catheter ablation (RFCA) has become an established treatment for ventricular arrhythmias (VA). Due to the challenging nature of visualizing lesion formation in real time and ensuring an effective transmural lesion, different surrogate measures of lesion quality have been used. The Ablation Index (AI) is a variable incorporating power delivery in its formula and combining it with CF and time in a weighted equation which aims at allowing for a more precise esti... Read More
Over the last decade, radiofrequency catheter ablation (RFCA) has become an established treatment for ventricular arrhythmias (VA). Due to the challenging nature of visualizing lesion formation in real time and ensuring an effective transmural lesion, different surrogate measures of lesion quality have been used. The Ablation Index (AI) is a variable incorporating power delivery in its formula and combining it with CF and time in a weighted equation which aims at allowing for a more precise estimation of lesion depth and quality when ablating VAs. AI guidance has previously been shown to improve outcomes in atrial and ventricular ablation in patients with premature ventricular complexes (PVC). However research on outcomes following AI-guidance for VT ablation specifically in patients with structural disease and prior myocardial infarction remains sparse. We aim at conducting a prospective observational multicenter registry investigating the efficacy and safety of AI-guided VA ablation in patient with ischemic and non-ischemic cardiomyopathy. Read Less
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Rush University Medical Center, Chicago, Illinois
Rush University Medical Center, Chicago, Illinois
Conditions: Ventricular Tachycardia, Ventricular Arrythmia, Cardiomyopathies
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy. Read Less
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: GSK Investigational Site, Goodyear, Arizona
GSK Investigational Site, Chicago, Illinois
Conditions: Neoplasms
Paid Clinical Trials in Chicago
The most successful treatments we have today for diseases like asthma, cancer, high blood pressure, and heart problems came from what we learned from clinical trials. This is why patients can enjoy a better quality of life and longer lifespan.
Paid research studies in Chicago are here to provide a monetary benefit for those willing to participate. Clinical trials often require a lot of time and commitment from participants. You would need to get tested all the time, visit the clinic regularly, and make lifestyle changes.
These trials also come with risks. Paid clinical trials in Chicago can motivate patients to participate, especially if they can’t afford treatment. Sponsors can cover expenses like parking fees, taking time off work, and transportation.
The compensation for Chicago paid studies reduces the financial burden and makes new treatments more accessible for people. It also reduces the dropout rates and maintains a consistent pool of participants throughout the trial.
Clinical Trials For Health Volunteers in Chicago
As a health volunteer, you become the cornerstone of progress. Your contributions set the standard for best practices in medical care.
You directly contribute to the development of new treatments and therapies. Your involvement can lead to breakthroughs that benefit not only the people of Chicago but potentially millions around the world.
Don’t miss out on the opportunity to be a part of medical advancements. Take the first step and browse our list of active and upcoming trials.
The Gut and Skin Microbiome in Vitiligo Disease Progression
Recruiting
Investigators plan to perform a pilot study that aims to characterize the microbiome of human vitiligo patients with both active and stable disease and compare this to the microbiome of age and sex matched controls. The investigators aim to answer the question whether the gut and skin microbiome of patients with vitiligo differs from the general population.
Investigators plan to perform a pilot study that aims to characterize the microbiome of human vitiligo patients with both active and stable disease and compare this to the microbiome of age and sex matched controls. The investigators aim to answer the question whether the gut and skin microbiome of patients with vitiligo differs from the general population. Read Less
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
05/02/2025
Locations: Northwestern University, Chicago, Illinois
Northwestern University, Chicago, Illinois
Conditions: Vitiligo, Healthy
Anti-mullerian Hormone Levels in Healthy Females
Recruiting
The purpose of this study is to have a better understanding of the normal blood levels of AMH in females from 0-18 years of age and how the blood AMH levels correspond to a female's reproductive development.
The purpose of this study is to have a better understanding of the normal blood levels of AMH in females from 0-18 years of age and how the blood AMH levels correspond to a female's reproductive development. Read Less
Gender:
FEMALE
Ages:
18 years and below
Trial Updated:
11/14/2024
Locations: Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois
Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Healthy
Mechanical Coring to Achieve Directional Skin Tightening
Recruiting
The objective of this clinical study is to evaluate the safety and efficacy of mechanical coring for directional skin tightening. This study is a prospective, up to 3 center, multiple skin treatment area study of the safety and efficacy of mechanical coring with directional closure to achieve directional skin tightening.
The objective of this clinical study is to evaluate the safety and efficacy of mechanical coring for directional skin tightening. This study is a prospective, up to 3 center, multiple skin treatment area study of the safety and efficacy of mechanical coring with directional closure to achieve directional skin tightening. Read Less
Gender:
ALL
Ages:
Between 30 years and 70 years
Trial Updated:
02/13/2024
Locations: Berman Skin Institute, Los Altos, California
DeNova Research, Chicago, Illinois
Conditions: Skin Tightening, Healthy Volunteers
Testing the Contribution of Orbitofrontal Cortex Networks to Decision-making
Recruiting
This research study examines the contribution of orbitofrontal cortex (OFC) networks to decision-making.
This research study examines the contribution of orbitofrontal cortex (OFC) networks to decision-making. Read Less
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
08/16/2024
Locations: Northwestern University, Chicago, Illinois
Northwestern University, Chicago, Illinois
Conditions: Healthy
Hyperpolarized 129Xe MRI Lung Health Cohort
Recruiting
A subset of young adults participating in the American Lung Association (ALA) Lung Health Cohort (LHC) will be imaged using Hyperpolarized 129Xe MRI to assess lung structure and function. Images will be used to improve the understanding of lung health and early lung abnormalities that may lead to chronic lung disease.
A subset of young adults participating in the American Lung Association (ALA) Lung Health Cohort (LHC) will be imaged using Hyperpolarized 129Xe MRI to assess lung structure and function. Images will be used to improve the understanding of lung health and early lung abnormalities that may lead to chronic lung disease. Read Less
Gender:
ALL
Ages:
Between 25 years and 35 years
Trial Updated:
04/01/2025
Locations: University of Illinois-Chicago, Chicago, Illinois
University of Illinois-Chicago, Chicago, Illinois
Conditions: Healthy
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B)
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with Hemophilia A or Hemophilia B, with or without inhibitors (Part B).
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with Hemophilia A or Hemophilia B, with or without inhibitors (Part B). Read Less
Gender:
MALE
Ages:
Between 18 years and 60 years
Trial Updated:
07/07/2025
Locations: California Clinical Trials Medical Group (CCTMG), Glendale, California
Rush University Medical Center, Chicago, Illinois
Conditions: Healthy Participants, Hemophilia A, Hemophilia B
Effects of Vibration on Motor Function of Survivors of Chronic Stroke
Recruiting
The aim of this study is to evaluate how vibration of the tendons enhances arm and hand training in survivors of chronic stroke.
The investigators hypothesize that wrist/elbow robotic training, combined with body awareness training will improve arm and hand function in individuals with chronic stroke.
The aim of this study is to evaluate how vibration of the tendons enhances arm and hand training in survivors of chronic stroke.
The investigators hypothesize that wrist/elbow robotic training, combined with body awareness training will improve arm and hand function in individuals with chronic stroke. Read Less
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/03/2024
Locations: Shirley Ryan AbilityLab, Chicago, Illinois
Shirley Ryan AbilityLab, Chicago, Illinois
Conditions: Stroke, Healthy
A Clinical Study of MK-1084 in Participants With Renal Impairment (MK-1084-010)
Recruiting
The goal of this study is to learn what happens to MK-1084 levels in a person's body over time. Researchers will measure what happens to MK-1084 levels in the body when it is given to people with moderate or severe renal impairment (RI) (meaning the kidneys do not work properly) as compared to people who are in good health. Researchers also want to learn about the safety of MK-1084 when it is given to people with RI and if people with RI can tolerate it.
The goal of this study is to learn what happens to MK-1084 levels in a person's body over time. Researchers will measure what happens to MK-1084 levels in the body when it is given to people with moderate or severe renal impairment (RI) (meaning the kidneys do not work properly) as compared to people who are in good health. Researchers also want to learn about the safety of MK-1084 when it is given to people with RI and if people with RI can tolerate it. Read Less
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/05/2025
Locations: Orlando Clinical Research Center ( Site 0002), Orlando, Florida
Research by Design ( Site 0001), Chicago, Illinois
Conditions: Healthy, Renal Impairment
A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)
Recruiting
The goal of the study is to learn what happens to levels of MK-5684 in people with severe renal impairment and end-stage renal disease versus a healthy person's body over time. Researchers will compare what happens to MK-5684 after hemodialysis in people with severe renal impairment and end-stage renal disease versus healthy people.
The goal of the study is to learn what happens to levels of MK-5684 in people with severe renal impairment and end-stage renal disease versus a healthy person's body over time. Researchers will compare what happens to MK-5684 after hemodialysis in people with severe renal impairment and end-stage renal disease versus healthy people. Read Less
Gender:
MALE
Ages:
Between 18 years and 85 years
Trial Updated:
08/01/2025
Locations: Orlando Clinical Research Center ( Site 0002), Orlando, Florida
Research by Design ( Site 0001), Chicago, Illinois
Conditions: Kidney Failure, Chronic, End-Stage Kidney Disease, Renal Failure, Chronic, Renal Failure, End-Stage, Healthy Participants
WIM Exosuit Wearable Soft Robot for Enhancing Walking Activity
Recruiting
This study is to develop, test, and optimize a soft hip wearable robot for individuals who have experience a stroke.
This study is to develop, test, and optimize a soft hip wearable robot for individuals who have experience a stroke. Read Less
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
07/08/2025
Locations: Shirley Ryan AbilityLab, Chicago, Illinois
Shirley Ryan AbilityLab, Chicago, Illinois
Conditions: Stroke, Healthy
Medical Discoveries and Innovation in Chicago
Prediction can improve healthcare.
The University of Chicago Medicine is working with Google to study how machine learning (ML) can boost patient care. Scientists are working on creating predictive models with ML. These models could help prevent expensive complications and unexpected hospital readmissions.
Over the last year, Google scientists have demonstrated how ML helps healthcare professionals detect breast cancer and avoid preventable vision loss. They’ve also converted research findings into practical medical tools and delivered alerts to doctors whose patients suffered from serious health issues.
Researchers in the Department of Medicine in Chicago secured a record-breaking $169 million in funding. They also effectively applied their fundamental research in real-world clinical settings, leading to significant breakthroughs. They published thousands of notable papers featured in high-profile journals. They conducted over 1,600 clinical research studies.
Why Chicago Is A Great Place For Clinical Research
Medical research opportunities in Chicago rely heavily on diverse patient data. Reports indicate that 45.33% of its residents are White, 29.22% are Black, 10.67% are from other races, 7.4% are Multiracial, 6.85% are Asian, 0.49% are Native American, and 0.04% are Native Hawaiian.